Overview

Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3)

Status:
Completed
Trial end date:
2019-08-07
Target enrollment:
Participant gender:
Summary
The purpose of study is to confirm the efficacy of DWP14012 Xmg, Once daily, compared to esomeprazole 40mg in patients with erosive gastroesophageal reflux disease.
Phase:
Phase 3
Details
Lead Sponsor:
Daewoong Pharmaceutical Co. LTD.
Treatments:
Esomeprazole